Free Trial
NASDAQ:UNCY

Unicycive Therapeutics (UNCY) Stock Price, News & Analysis

Unicycive Therapeutics logo
$5.01 -0.24 (-4.57%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$5.01 +0.00 (+0.02%)
As of 07/11/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Unicycive Therapeutics Stock (NASDAQ:UNCY)

Key Stats

Today's Range
$4.83
$5.26
50-Day Range
$4.64
$9.00
52-Week Range
$2.02
$11.00
Volume
808,621 shs
Average Volume
277,777 shs
Market Capitalization
$63.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.00
Consensus Rating
Buy

Company Overview

Unicycive Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

UNCY MarketRank™: 

Unicycive Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 343rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Unicycive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Unicycive Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Unicycive Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Unicycive Therapeutics are expected to grow in the coming year, from ($0.23) to ($0.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Unicycive Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Unicycive Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Unicycive Therapeutics has a P/B Ratio of 6.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.90% of the float of Unicycive Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Unicycive Therapeutics has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Unicycive Therapeutics has recently decreased by 70.67%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Unicycive Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Unicycive Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.90% of the float of Unicycive Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Unicycive Therapeutics has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Unicycive Therapeutics has recently decreased by 70.67%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Unicycive Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Unicycive Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 22 people have searched for UNCY on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
  • MarketBeat Follows

    Only 7 people have added Unicycive Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Unicycive Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.71% of the stock of Unicycive Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    40.42% of the stock of Unicycive Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Unicycive Therapeutics' insider trading history.
Receive UNCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unicycive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UNCY Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Headlines

UNCY Stock Analysis - Frequently Asked Questions

Unicycive Therapeutics' stock was trading at $7.9420 at the start of the year. Since then, UNCY stock has decreased by 36.9% and is now trading at $5.01.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) released its earnings results on Wednesday, May, 14th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($1.40) by $0.90.

Unicycive Therapeutics's stock reverse split on the morning of Friday, June 20th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 19th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Unicycive Therapeutics (UNCY) raised $25 million in an initial public offering on Tuesday, July 13th 2021. The company issued 4,600,000 shares at $5.00-$6.00 per share. Roth Capital Partners acted as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager.

Shares of UNCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Unicycive Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), ADC Therapeutics (ADCT), Citius Pharmaceuticals (CTXR), DocGo (DCGO), NVIDIA (NVDA) and Adicet Bio (ACET).

Company Calendar

Last Earnings
5/14/2025
Today
7/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:UNCY
CIK
1766140
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

High Price Target
$90.00
Low Price Target
$30.00
Potential Upside/Downside
+1,097.6%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$36.73 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-277.30%
Return on Assets
-61.53%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.64
Quick Ratio
1.64

Sales & Book Value

Annual Sales
$680 thousand
Price / Sales
93.13
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.72 per share
Price / Book
6.96

Miscellaneous

Outstanding Shares
12,640,000
Free Float
11,287,000
Market Cap
$63.33 million
Optionable
Not Optionable
Beta
1.89
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:UNCY) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners